Back to Search
NEIL BANDER, M.D.
M.D.
Urology Physician
NPI: 1518223213Individual
Specialties, Licenses & Credentials
Urology PhysicianPrimary
Urology
Code: 208800000X
126231-1(NY)
Research & Publications (20)
Technology insight: monoclonal antibody imaging of prostate cancer.
PMID 16607370·Nat Clin Pract Urol·2006
6-review
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
PMID 15837970·J Clin Oncol·2005
3-trial
Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.
PMID 14571414·Semin Oncol·2003
6-review
Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.
PMID 14532761·J Urol·2003
3-trial
Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.
PMID 19575420·Prostate·2009
8-other
Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy.
PMID 18613203·ChemMedChem·2008
8-other
Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2.
PMID 17912448·Int J Oncol·2007
7-preclinical
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.
PMID 17290063·J Clin Oncol·2007
3-trial
Differing effects of microtubule depolymerizing and stabilizing chemotherapeutic agents on t-SNARE-mediated apical targeting of prostate-specific membrane antigen.
PMID 17041090·Mol Cancer Ther·2006
7-preclinical
Clinical utility of radiolabeled monoclonal antibodies in prostate cancer.
PMID 16729907·Clin Genitourin Cancer·2006
6-review
Antibody-based therapeutics: focus on prostate cancer.
PMID 16408160·Cancer Metastasis Rev·2005
6-review
Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.
PMID 16203821·Clin Cancer Res·2005
3-trial
N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy.
PMID 15897234·Mol Cancer Ther·2005
7-preclinical
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
PMID 15872360·J Nucl Med·2005
3-trial
Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
PMID 15809486·J Nucl Med·2005
3-trial
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.
PMID 15173215·J Clin Oncol·2004
3-trial
Determination of immunoreactive fraction of radiolabeled monoclonal antibodies: what is an appropriate method?
PMID 15665617·Cancer Biother Radiopharm·2004
4-observational
Downregulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas.
PMID 15188008·Br J Cancer·2004
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 525 EAST 68TH STREET, F-900
NEW YORK, NY 10065 - Phone
- (212) 746-5493
Quick Facts
- NPI
- 1518223213
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile